U-HIV.com Blog

02 June 2026, Tu

Delstrigo is a Merck fixed-dose HIV-1 treatment containing doravirine, lamivudine and tenofovir DF. This article explains whether official generics exist and what alternatives patients usually discuss with their physician.

Read more
01 June 2026, Mo

Rutinib Cream (RUXOLITINIB 1.5%) is a ruxolitinib-based topical cream and a local JAK inhibitor. This article explains what the medicine is, which skin conditions ruxolitinib cream is discussed for, and why its appearance became an important step in dermatology.

Read more
21 May 2026, Th

Tofamark (Tofacitinib 5mg) belongs to modern targeted medicines based on tofacitinib. This article explains which diseases this therapy class is used for, how it differs from conventional medicines, and why the decision to use it must be made by a doctor.

Read more
08 May 2026, Fr

Taffic is one of the in-demand antiretroviral medicines from India. This article covers the key points: composition, package checks, delivery and safety of medical prescribing.

Read more
14 April 2026, Tu

Spegra часто ищут как современный комбинированный препарат для АРВ-терапии. Разбираем, что важно уточнить перед заказом и почему схему лечения должен подбирать врач.

Read more
22 March 2026, Su

Twinaqt интересует пациентов, которые ищут препараты для АРВ-терапии из Индии. Рассказываем, какие данные важно проверить до заказа.

Read more
16 May 2023, Tu

The US Centers for Disease Control and Prevention (CDC) filed a lawsuit against Gilead Sciences for patent infringement on Truvada and Descovy, which are used as pre-exposure prophylaxis (PrEP) for HIV prevention.

Read more
15 May 2023, Mo

Drug use is prevalent in prison systems worldwide, and the levels of HIV and hepatitis C, which can be transmitted through drug injection and sex, are also higher among people in prisons than the general population. However, prisons are often overlooked in efforts to combat these epidemics.

Read more
13 December 2022, Tu

Leggat et al. report the results of a phase 1 clinical trial showing that a germline-targeting priming immunogen was safe and feasible and induced targeted bnAb-precursor responses in 97% of vaccine recipients at substantial frequencies in each individual

Read more
13 April 2021, Tu

The first preclinical studies have shown that the method cleans infected cells from "sleeping" HIV by 100%.

Read more